<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shuman, Jill</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Ullmann, Andrew J.</style></author><author><style face="normal" font="default" size="100%">Goff, Debra</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Additional Results From SECURE</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-06-23 15:14:42</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">8-9</style></pages><abstract><style  face="normal" font="default" size="100%">Data from the SECURE trial suggested that isavuconazole was not inferior to voriconazole when treating invasive fungal diseases. Data from 2 subsets of SECURE now show that patients taking isavuconazole are less likely to suffer from treatment-emergent adverse events and that the drug is both safe and effective for obese patients.</style></abstract><number><style face="normal" font="default" size="100%">48</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>